Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Aclaris Therapeutics ( (ACRS) ) is now available.
On January 12, 2026, Aclaris Therapeutics updated its corporate overview presentation to highlight a broadened inflammation and immunology pipeline and a strategy centered on innovative oral and bispecific or multispecific antibody therapies for Th1-, Th2- and Th17-mediated diseases. The presentation underscored four anticipated clinical programs and multiple potential value inflection points in 2026, including progress on bosakitug (ATI-045), ATI-052, ATI-2138, next-generation ITK-selective inhibitors, and bispecific antibodies across dermatology, respiratory and gastrointestinal indications, while emphasizing prudent capital management and the need for strategic partnerships, moves that could materially influence its competitive position and long-term growth prospects in large, underserved markets.
The most recent analyst rating on (ACRS) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Aclaris Therapeutics stock, see the ACRS Stock Forecast page.
Spark’s Take on ACRS Stock
According to Spark, TipRanks’ AI Analyst, ACRS is a Neutral.
The score is mainly constrained by weak financial performance (large losses, declining TTM revenue, and ongoing cash burn). Technicals are mixed but not supportive in the near term, and valuation is difficult to justify with a negative P/E. Offsetting these, corporate events are positive with encouraging early clinical data and visible next development steps.
To see Spark’s full report on ACRS stock, click here.
More about Aclaris Therapeutics
Aclaris Therapeutics is a biopharmaceutical company focused on inflammation and immunology, developing oral kinase inhibitors and antibody-based therapies aimed at validated immune targets such as TSLP, IL-4R, ITK and JAK3. Its pipeline targets large dermatologic, respiratory and gastrointestinal indications, including atopic dermatitis, asthma, COPD, alopecia areata, vitiligo and other immune-mediated diseases, positioning the company in sizeable markets with substantial unmet medical need.
Average Trading Volume: 1,336,517
Technical Sentiment Signal: Buy
Current Market Cap: $290.4M
For a thorough assessment of ACRS stock, go to TipRanks’ Stock Analysis page.